Shares of Waters Corp. WAT sank 0.04% to $385.62 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.02% to 5,985.38 ...

About Waters Corporation (www.waters.com) Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal ...

"The UK Government is delighted that Waters Corporation is opening a new site at Longbridge. This investment brings new jobs and innovative new technology in precision engineering into the West ...

"The UK Government is delighted that Waters Corporation is opening a new site at Longbridge. This investment brings new jobs and innovative new technology in precision engineering into the West ...

Newly built 45,000 sq ft facility houses engineering and skilled manufacturing employees at Longbridge Business Park, a specialized hub for science and technology. Waters triples manufacturing ...

Despite a 13% stock appreciation, I maintain a neutral stance on Waters Corporation due to factors outlined in this report. Q3 FY'24 results show mixed regional performance, with China sales still ...

LONGBRIDGE, England, Nov. 13, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced the official opening of its new 45,000 square foot manufacturing facility at the Longbridge Business Park ...

November 11, 2024--(BUSINESS WIRE)--Geron Corporation (Nasdaq ... today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as ...

November 11, 2024--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the ...